ISG
6.2.2024 15:01:33 CET | Business Wire | Press release
With the threat of recession still looming, two-thirds of European insurance industry leaders plan to expedite their digitalization programs to improve the customer journey and enhance operational efficiencies, according to new survey research from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.
The ISG "Pulse Check - State of the European Insurance Industry" survey, conducted in the fourth quarter of 2023, surveyed nearly 270 business decision-makers and IT leaders in the European insurance industry and found 66 percent plan to increase their digital investments in the next two years, including 68 percent who say they will invest in payment channels, 63 percent each in cybersecurity and augmented and virtual reality, and 59 percent in artificial intelligence.
Survey participants said their two main strategic priorities are acquiring new customers, identified as a top priority by 85 percent of respondents, and leveraging digital channels to develop new business opportunities (74 percent). Increased investments in digital offerings and personalized customer services will help drive customer acquisition and retention, the ISG report noted.
"’Digital first’ is the focus as European insurers implement next-generation technologies that promise the quickest return on investment for their core businesses and to improve their market position,” said Steve Hall, president of ISG EMEA and the firm’s chief AI officer. "Process and decision automation and data management will help create human-centered, technology-enabled businesses that leverage rapidly evolving digital technology to reshape work, lower costs and improve service. AI will undoubtedly be an additional accelerator.”
The survey found demand for artificial intelligence (AI) is experiencing particularly strong growth. Thirteen percent of respondents report their annual budget for AI is already set at more than €1 million, and six out of ten expect to receive additional funding in 2024. Enterprises indicate they plan to leverage large language models alongside established AI methods such as natural language processing and machine learning.
AI development is still at an early stage for many respondents, with half of companies (50 percent) experimenting with prototypes and only 6 percent actively developing enterprise-wide AI solutions. Eighteen percent of respondents say technologies such as augmented reality (AR) and virtual reality (VR) are being used to reduce business insurance losses through preventive maintenance.
Ninety-one percent of respondents consider improving the effectiveness of customer data management a critical investment priority. Data silos remain a challenge, with only about one-fifth of existing customer data being effectively utilized, according to the ISG research.
Cybersecurity is another area of focus as enterprises increasingly rely on digital infrastructure that may expose assets to business interruption and cyber-attacks. Investments in digital risk management will continue to increase, particularly in cybersecurity and AI, to offer “customer trust” as a key differentiator and meet increasing regulations. Sixty-three percent of respondents expect their cybersecurity budgets to increase between 2024 and 2026 in response to escalating risks and regulatory demands.
"Insurers are prioritizing investments in AI, legacy modernization and IT security. Strategic partnerships can increase access to digital capabilities, process knowledge and specialized talent while expanding market access and sharing development risk,” Hall added. "The share of organizations that see consolidation of their service provider portfolio as a top IT priority is growing significantly, from 59 percent in 2022 to 93 percent in 2023.”
Striking a balance between insourcing and outsourcing is critical given the evolving dynamics of the labor market and the need to attract and retain IT talent, the report said. The percent of survey respondents who plan to invest in insourcing (78 percent) is almost the same as the number who plan to invest in outsourcing (77 percent). Sixty-eight percent of decision-makers see improving talent management as a pressing business imperative.
"As tech companies and insurtech startups become more attractive employers for young, tech-savvy talent, traditional carriers are challenged to attract and retain top talent," Hall concluded. "High-quality talent management is becoming a critical factor in meeting transformative technology demands."
The ISG "Pulse Check – State of European Insurance Industry 2024” report is available for download on this website.
About ISG
ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206423163/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
